Results 31 to 40 of about 1,394,911 (165)
Recent advances in the mechanisms and treatment of immune thrombocytopenia
EBioMedicine, 2022 Summary: Primary immune thrombocytopenia is an autoimmune disease associated with a reduced peripheral blood platelet count. The phenotype is variable with some patients suffering no bleeding whilst others have severe bleeding which may be fatal ...
Drew Provan, John W. Semple
doaj +1 more source
Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring Plateletpheresis [PDF]
, 2016 Immune thrombocytopenic purpura (ITP) causes thrombocytopenia through the autoimmune destruction of platelets. Corticosteroids remain the first line of therapy, and traditionally splenectomy has been the second.
Jacquelyn Zimmerman +2 more
core +1 more source
Recent advance of pathogenesis of TPO in thrombocytes and its clinical use in patients with chronic liver disease [PDF]
Xin yixuePatients with chronic liver disease frequently exhibit thrombocytopenia， the etiology of which is intricate and not yet fully understood. As research into the association between chronic liver disease and thrombocytopenia has progressed in recent years ...
PI Sainan, LI Liang, YANG Mo, CHEN Youpeng
doaj +1 more source
Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
Регуляторные исследования и экспертиза лекарственных средств, 2020 Idiopathic thrombocytopenic purpura (ITP), or primary immune thrombocytopenia, is an orphan disease associated with thrombocytopenia. One of the most recent and promising approaches to ITP treatment is the use of thrombopoietin receptor agonists (TPO-RAs)
A. G. Solodovnikov +2 more
doaj +1 more source
Therapeutics and Clinical Risk Management, 2022 Galina Tsykunova,1– 3 Waleed Ghanima2– 4 1Department of Hematology, Haukeland University Hospital, Bergen, Norway; 2Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 3Department of Hemato-Oncology, Østfold Hospital, Grålum, Norway ...
Tsykunova G, Ghanima W
doaj
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
, 2007 Thrombopoietin is the primary regulator of platelet production. We exploited two naturally occurring miniproteins of the inhibitor cystine knot family as stable and rigid scaffolds for the incorporation of peptide sequences that have been shown to act as
Krause, Sebastian +5 more
core +1 more source
Repurposing FDA‐Approved Drugs to Inhibit Fungal PPTases for Broad‐Spectrum Synergy
Advanced Science, EarlyView.Fungal secondary metabolites serve as crucial virulence effectors; however, the potential of their biosynthetic pathways as antifungal targets remains inadequately comprehended. Repurposed FDA‐approved drugs inhibit fungal PPTase (essential for secondary metabolism) in vivo.
Zili Song +7 more
wiley +1 more source
Platelets, 2022 The thrombopoietin mimetic peptide for injection is a second-generation thrombopoietin receptor agonist (TPO-RA) used in the treatment of patients with immune thrombocytopenia.
Xiao-Yan Sheng +6 more
doaj +1 more source
Advanced Science, EarlyView.This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo +10 more
wiley +1 more source